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Abstract
Background: Postpartum depression is a disease with a prevalence of 20% that has deleterious consequences not
only for the mother but also for the baby and can cause delays in physical, social and cognitive development. In
this context, the European Union Committee on Public Health has declared it essential that preventative measures
are taken by centres providing care for women with a multidisciplinary approach. PROGEA is a multicentre, single-blind
randomized, 3-year, longitudinal clinical trial aiming to evaluate the efficacy of a psychoeducational programme in
preventing postpartum depression in at-risk women, based on a range of clinical variables, and explore prognostic
factors. This paper describes the methods and rationale behind the study.
Methods: We will study women receiving treatment as usual plus a psychoeducation cognitive behavioural therapy
(CBT)-based intervention and a control group receiving only treatment as usual. The sample will be recruited from an
incidental sampling of pregnant women in two health regions. We will recruit 600 women in the third trimester of
pregnancy who consent to take part in the study. Almost half of the women, about 280, would be expected to have
some risk factors for postpartum depression. All those found to have risk factors will be evaluated, and we estimate
that a quarter will be classified as at-risk of developing postpartum depression as measured with the Edinburgh
Postnatal Depression Scale. This subset will be randomly allocated to receive treatment as usual with or without the
CBT intervention. Six sessions of CBT (1 individual and 5 group) will be offered by a psychologist.
Discussion: Findings from this study will be used to design a definitive study that will examine the clinical and
cost-effectiveness of the CBT-based intervention in improving the mood of women in the postpartum period.
Trial Registration: ClinicalTrials.gov Identifier: NCT02323152; Date: December 2014.
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Background
Treatment of major depression is an objective of the
European Union and in recent years the World Health
Organization (WHO) has identified improving maternal
mental health as a fundamental part of the Millennium
Development Goals [1]. Today, peripartum depression
(as defined in DSM-V) [2] is attracting greater attention
from clinicians and researchers, as a condition that
affects not only the mother, but also the health and
development of the child health [3–5]; for these reasons,
its prevention is particularly important [6].
The most frequent psychopathological disorders in
women during pregnancy and the puerperium are
depression, stress and anxiety [7]. Postpartum depres-
sion (PPD), in particular, is one of the most common
complications in this period, affecting nearly 20% of all
women after childbirth each year [8], but many cases go
undetected and there is no international consensus on
the best screening method [9].
PPD is defined as development of a major depressive
episode with onset during pregnancy or within 4 weeks
after childbirth and in which depressive symptoms are
present for at least 2 weeks [2]. The risk factors for
developing PPD include biological variables such as
hormonal changes that women experience during preg-
nancy and after delivery; these are necessary to ensure
their health during this period and are part of preparing
the body for both childbirth and breastfeeding, but can
cause depression in a subgroup of vulnerable women
[10]. In addition to biological factors, there are psycho-
social factors, among which we should highlight a
personal or family history of depression or PPD and hav-
ing experienced mood depression or anxiety during
pregnancy [11].
Specifically, rates of PPD of more than 70% have
been found in women with previous depressive symp-
toms [12]. Other risk factors described include:
personal vulnerability of women [13], the tempera-
ment of the child [14], poor family and social support
during the postpartum period [6, 15], relationship
problems during pregnancy [16, 17], traumatic experi-
ences in previous pregnancies [18] or low socioeco-
nomic status [19].
Psychological therapy for depression has shown to be
an effective treatment in depressed patients of all ages
and all degrees of severity, including PPD [20]. Given
the consequences of the disease, another strategy would
be to administer preventive treatment with a lasting ef-
fect that could protect women against developing this
type of depression. A systematic review found that 13/17
studies with successful psychological treatment targeted
an at-risk population, and 4/7 trials using interpersonal
therapy demonstrated success of the intervention versus
a control condition [8].
The aim of this study was to identify women at risk of
PPD using a protocol [21], investigate the efficacy of a
structured programme of psychoeducational therapy
designed ad hoc in preventing the development of PPD
in at-risk women and explore prognostic factors for this
type of depression.
Methods/Design
We registered this single-blind randomized clinical trial in
2014 (identifier NCT02323152). Women will be recruited
in the third trimester of pregnancy from 2015 to the
completion of the study. Women that agree to participate
and sign the informed consent form will then be assessed
through a first screening visit by their reference midwife;
specifically, the midwife will record sociodemographic
data and the presence of various previously described risk
factors, including the personality vulnerability of the
woman and her socioeconomic status.
Women with at least one risk factor will progress to
the next phase of the study and will be assessed between
8 and 15 days after the birth of their baby, at the Araba
University Hospital. Clinical data will be collected relat-
ing to the delivery. We will also evaluate the women’s
mood with the Edinburgh Postnatal Depression Scale
(EPDS) [22], the child’s temperament with the Merrill-
Palmer-Revised Scales of Development [23] and the
current and overall physical activity of women with the
International Physical Activity Questionnaire (IPAQ)
[24] and Global Physical Activity Questionnaire (GPAQ)
[25] using the Spanish versions of these tools. A score
between 7.5 and 12.5 on the EPDS indicates depression
risk and women with scores in this range will progress
to the next phase of the study. In this phase, the partici-
pants will be randomized with Random Allocation
Software 1:1 to the experimental or control group (treat-
ment as usual). Women in the experimental group will
receive six (1 individual and 5 group) sessions of the
psychoeducational intervention and their status will be
evaluated weekly. The control group will continue to
have regular appointments with the midwife and gynae-
cologist and will be assessed again 6 weeks after inclu-
sion in the trial.
We will recruit patients from five health centres in
Vitoria and two health centres in Donostia, and the
study is being coordinated by the Psychiatry Research
team of Araba University Hospital, which is a member
of the Center for Biomedical Research Mental Health
Network (CIBERSAM). Patients meeting all the inclu-
sion criteria and none of the exclusion criteria (listed
below) will be included in the study.
The trial will be conducted in accordance with good
clinical research practice, enabling the research to be
carried out with low risk of bias and a high degree of
external validity.
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Inclusion criteria
1. General criteria for inclusion in the 1st phase of the
study:
a) Pregnant women in their third trimester. In the
case of women under 18, inclusion will be
notified to the Finance Ministry
b) Written informed consent of the participant. In
the case of women under 18, their legal
representative also must sign the document.
2. Inclusion criteria for 2nd phase of the study:
a) Presence of one or more of the following risk
factors for developing PPD, assessed in the 3rd
trimester of pregnancy:
 Depressive or anxious symptoms during
pregnancy
 Personal history of severe mental disorder
(schizophrenia and other psychoses, bipolar
disorder, depressive disorder)
 Family history of severe mental disorder
 Concomitant medical diseases associated
with depression (diabetes, heart disease,
hypertension, obesity)
 Low or very low socioeconomic status
 Lack of support (partner, family, friends or
others).
b) A score ≥7.5 in the EPDS questionnaire
when assessed 8 to 15 days after delivery. In
the study of Vega-Dienstmaier et al. [22], no
women with scores lower than 7.5 were
diagnosed with DPP (sensitivity and positive
predictive value of 100%). Therefore, we
have decided to select patients with scores
of 7.5 or higher on the EPDS scale.
Exclusion criteria
1. Mental retardation
2. Worsening of a severe mental disorder that could
hinder understanding of the objectives of the study
3. Language difficulties that impede verbal
comprehension, reading and/or writing
4. Presence of a major depressive episode according
to the DSM-IV-TR (depressive symptoms of
sufficient intensity and duration longer than
2 weeks).
All participants will be informed that they will be
randomized to one of the two study groups and will only
be included if they give their informed consent to par-
ticipate in the study. Women in both groups will be
assessed at baseline (pre-intervention) and 6 weeks
(post-intervention).
Ethical considerations
The study will be conducted in compliance with local
regulations and internationally established principles of
the Declaration of Helsinki [26]. The study and protocol
have been approved by the Clinical Research Ethics
Committee of the Basque Country (Araba University
Hospital: HS/PI2011013).
Sample size
After a thorough review of the literature and using the
Ene 2.0 [27] software, we calculated that for a statistical
power of 90%, with a significance level of 5%, a sample
of 30 patients per group will allow us to detect mean
differences of 5.5 points on the EPDS between the ex-
perimental group and the control group (alpha = 0.05,
beta = 0.10, N = 126). To achieve this sample, 600 partic-
ipants in the third trimester of pregnancy will be
screened for eligibility. Of the total, about 280 are ex-
pected to have at least one risk factor and will progress
to the second phase of the study. Of these, we estimate
that a quarter of the women will score 7.5 or higher on
the EPDS, which would leave approximately 60 women
to be randomized to the two arms of the trial.
Randomization
All women with risk of PPD that meet the inclusion cri-
teria and none of the exclusion criteria will be random-
ized with Random Allocation Software. For this purpose,
all the groups from the participating hospitals will send
the initials of each patient recruited to the study coord-
inator who will specify the allocation of the patient (to
the control or intervention group); the person in charge
of the assessments will be blind to this process.
Patient assessment
Data on the wide range of clinical and demographic vari-
ables detailed below will be gathered using a data collec-
tion form. All candidate women will be assessed in the
third trimester of pregnancy in order to screen for the
presence of any of the aforementioned risk factors.
Scales to assess socioeconomic status and personality
vulnerability will also be administered in this screening.
The next assessment will be the baseline assessment of
all the women that are found to have at least one risk
factor for PPD in the screening between 8 and 15 days
after the childbirth. At this point, we will assess the
mother’s physical activity and child’s temperament and
measure the depressed mood of the mother with the
EPDS. Women scoring ≥ 7.5 who are then then random-
ized to one of the two groups (control vs experimental)
will be assessed weekly until the completion of six
psychoeducational sessions, nearly 2 months after the
baseline assessment. The control groups will be also re-
assessed after the same interval.
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Demographic and other personal data
We will collect data on age, sex, ethnicity, level of
education, living arrangements, employment status, prob-
lems in the delivery and medication use (in such cases).
Risk factors
We have compiled a list of risk factors (RF) associated
with PPD based on an electronic search in PubMed. The
midwife will note if the pregnant women have any of
these factors.
Specifically, we included the following RFs as the most
closely related to PPD:
 Depressive or anxious pathology during pregnancy
 Personal history of severe mental disorder
(schizophrenia and other psychoses, bipolar
disorder, depressive disorder)
 Family history of severe mental disorder
 Concomitant medical diseases associated with
depression (diabetes, heart disease, hypertension,
obesity)
 Low or very low socioeconomic status
 Lack of support for women (partner, family, friends
or others).
Mood assessment
The EPDS will be used to assess participants’ depressive
symptoms [22]. This 10-item self-report tool is designed
to screen women for symptoms of emotional distress
during pregnancy and the postnatal period.
Vulnerable personality assessment
The Vulnerable Personality Style Questionnaire (VPSQ)
is a nine-item self-report scale developed to assess
personality traits which increase the risk of PPD [13].
Physical Activity Questionnaires
The IPAQ provides a set of well-developed instruments
that can be used internationally to obtain comparable es-
timates of physical activity. The long version we will use
provides the detailed information often required in re-
search work or for evaluation purposes [24].
The GPAQ was developed by WHO for monitoring
physical activity [25]. It collects information about par-
ticipation in physical activity and sedentary behaviour in
three domains:
 Activity at work
 Activity related to traveling to and from places
 Leisure activities
Children’s temperament style
MP-R: We will measure the child’s temperament with
the Merrill-Palmer–Revised Scales of Development [23].
This instrument evaluates five main areas of develop-
ment: cognition, language and communication, motor
skills, adaptive behaviour, and socioemotional domains.
It provides information about global development of
the child to assess the presence of possible delays in
some areas.
All the instruments to be used have demonstrated ad-
equate psychometric properties and have been used in
many other studies. Interviews will be conducted by
clinicians who have good inter-rater reliability for the
scales used.
Intervention programme
Our Postpartum Depression Prevention Programme
(PDPP) consists of six 1-h weekly sessions, for 2 months,
focused on improving the information that the women
have about depression syndrome, patient insight into
their illness, early intervention for prevention, healthy
lifestyles, techniques for managing anxiety, social skills
and problem solving.
The first session is individual, and the remaining ones
are group sessions. The programme has an open format.
That is, each woman that is randomized to the experi-
mental group will directly enter the group, and start re-
ceiving the intervention, regardless of the session
number. The rationale behind this is that women should
not have to wait until a group is formed. In this way, we
minimize the risk of the symptoms worsening.
The programme includes the following sessions:
1. What is PPD? Etiological and trigger factors
2. Risk Factors for PPD
3. How to manage negative thoughts
4. Techniques for reducing stress and anxiety
5. Problem-solving techniques
6. Healthy lifestyle and technical guidance on seeking
practical solutions
The psychoeducational sessions will only be run in
Araba University Hospital. Further, the therapists will
have a specific training to give the psychoeducational
intervention to all women in the same way, and provide
the same information, enhancing the reliability of the
study.
Lastly, if participants have any question about the ses-
sions, or about their condition, they will be able to call a
telephone helpline in working hours (between 08.00 and
15.00 from Monday to Friday). The aim of this service is
to facilitate participants’ access to information and ad-
dress any questions they might have.
Treatment as usual
Treatment as usual refers to the treatment that is rou-
tinely provided to pregnant women in the Spanish
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National Health Service. It consists of ambulatory ap-
pointments with their midwives and gynaecologist. They
will not receive any therapeutic input from the
psychologist.
Expected timetable for the study
Figure 1 shows the flow of women though in the study.
Data processing
Comparisons of baseline characteristics of the sample
will be made with χ2-tests for categorical variables and
the Student’s t-test or Mann Whitney U test for quanti-
tative variables, depending on the distribution of the
data. Differences in mood symptomatology during treat-
ment will be examined using Wilcoxon signed-rank test
for the within-group analyses and the Mann–Whitney U
test for the between group analyses. The latter will also
be used to analyse variation in EPDS scores between
groups. On the other hand, cut-off points for the EPDS
will be established and differences in the categorical
variables created will be analysed with χ2-tests. Linear
regression models will be performed for each group to
evaluate the influence of the child’s temperament and
global and daily activity during treatment on mood
symptoms.
Univariate analyses of covariance will be conducted to
investigate differences between groups. For this, the inde-
pendent variable will be the group assignment (treatment
as usual plus psychoeducation treatment versus treatment
as usual alone) and the dependent variables will be the
respective clinical or functional outcome scores post-
treatment. This analysis will be performed on an
intention-to-treat basis, with women being analysed in the
treatment group to which they were randomized. In
addition, a logistic regression model will be used to assess
the relationships between clinical variables.
Finally, we will also build an ordinal regression model
to explore factors associated with having depression after
the intervention. The categorical variable of the EPDS
assessed post-intervention will be used as the dependent
Fig. 1 CONSORT diagram. The CONSORT diagram illustrates and reports the progression of the participants through the different points of
the study
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variable, while risk factors evaluated at baseline will be
the independent variables.
The outcomes will be reported with 95% confidence
intervals. All data will be analysed using IBM SPSS
Statistics v22.
Discussion
This study will provide information about the effective-
ness of a new psychoeducational programme specifically
designed to prevent PPD in at-risk women. Should it be
found to be effective, this programme could have an
important role in preventing this type of depression, a
severe mental illness, and its deleterious consequences
both in women and in their family including the new-
born infant.
The strengths of the study include targeting a defined
sample of pregnant women at risk of depressive disorder
according to the literature reviewed. The implementa-
tion of a preventive programme focused on the mental
health of women during pregnancy and the postpartum
period is, in itself, an important aspect of the study, as
existing postpartum care programmes tend to be related
to the baby and the reproductive system of the woman,
as well as the treatment of health problems, but not to
prevention. With this study, we underline that it is
essential to pay close attention to the overall wellbeing
of women including their mental health, especially in
women with recognized risk factors.
Trial status
Recruitment started on 8 September 2015, and the first
participant consented on 10 September 2015. At the
time of preparing this manuscript, 59 people have given
consent. Recruitment is due to finish at the end of
August 2017.
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